Literature DB >> 30324114

Status of FAS and FAS Ligand Gene Polymorphisms in Patients with Breast Cancer in Northeastern IRAN.

Seyed Amir Jalali1, Fatemeh Homaei Shandiz2, Jalil Tavakol Afshari3,4, Maryam Davarpanah Tanha Ghochan5, Amin Reza Nikpoor3,4, Mojgan Mohammadi6,3.   

Abstract

BACKGROUND: The First apoptosis signal (FAS) and First apoptosis signal ligand (FASL) genes initiate the apoptosis pathway, playing a central role in the tumor growth and metastasis. Gene polymorphisms including -1377 G/A in the promoter region of FAS and -844 C/T in the promoter region of FASL have shown to change the transcription activities of these genes.
METHODS: In this study we evaluated association of these polymorphisms with risk of metastasis of breast cancer, in a population selected from Mashhad, Iran. A total of 115 patients with breast cancer and 115 controls were recruited in this case-control study. Polymerase Chain Reaction-based Restriction Fragment Length Polymorphism (PCR-RFLP) was applied for genotyping on extracted DNA from participant's blood. Unconditional logistic regression was used to estimate cancer risk by calculating odds ratios (OR) and their 95% confidence intervals (95% CIs).
RESULTS: There was no significant association between these genetic polymorphisms and breast cancer risk. Additionally, our results showed no significant influence from the above mentioned gene polymorphisms on metastasis of breast cancer.
CONCLUSION: These results suggest that the FAS-1377G/A and FASL-844 C/T gene polymorphism don't have much influence on the susceptibility to metastasis of breast cancer in northeastern Iranian population. Therefore, we suggest to investigate impact of other candidate gene polymorphisms on metastasis of breast cancer for future research.

Entities:  

Keywords:  Breast cancer; Fas Ligand; Fas receptor; Gene polymorphism; Metastasis

Year:  2018        PMID: 30324114      PMCID: PMC6175584     

Source DB:  PubMed          Journal:  Rep Biochem Mol Biol        ISSN: 2322-3480


  33 in total

1.  FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies.

Authors:  Zhizhong Zhang; Hengchuan Xue; Weida Gong; Meilin Wang; Lin Yuan; Suping Han; Zhengdong Zhang
Journal:  Carcinogenesis       Date:  2009-01-23       Impact factor: 4.944

2.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

3.  FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China.

Authors:  Meilin Wang; Dongmei Wu; Ming Tan; Weida Gong; Hengchuan Xue; Hongbin Shen; Zhengdong Zhang
Journal:  Biochem Genet       Date:  2009-06-30       Impact factor: 1.890

Review 4.  Apoptosis in cancer.

Authors:  S W Lowe; A W Lin
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

5.  Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.

Authors:  Bailin Zhang; Tong Sun; Liyan Xue; Xiaohong Han; Baoning Zhang; Ning Lu; Yuankai Shi; Wen Tan; Yifeng Zhou; Dan Zhao; Xuemei Zhang; Yongli Guo; Dongxin Lin
Journal:  Carcinogenesis       Date:  2006-12-20       Impact factor: 4.944

Review 6.  Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual.

Authors:  S Eva Singletary; James L Connolly
Journal:  CA Cancer J Clin       Date:  2006 Jan-Feb       Impact factor: 508.702

7.  Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene.

Authors:  Q R Huang; D Morris; N Manolios
Journal:  Mol Immunol       Date:  1997-06       Impact factor: 4.407

8.  The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.

Authors:  Zhizhong Zhang; Lixin Qiu; Meilin Wang; Na Tong; Jin Li; Zhengdong Zhang
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

9.  Functional polymorphisms in FAS/FASL system increase the risk of neuroblastoma in Chinese population.

Authors:  Wei Han; Yuling Zhou; Rong Zhong; Chen Wu; Ranran Song; Li Liu; Li Zou; Yan Qiao; Kan Zhai; Jiang Chang; Liming Huang; Li Liu; Xuzai Lu; Jiao Lou; Dianke Yu; Wen Tan; Jinzhe Zhang; Huanmin Wang; Xiaoping Miao
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

Review 10.  Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies.

Authors:  Yeqiong Xu; Bangshun He; Rui Li; Yuqin Pan; Tianyi Gao; Qiwen Deng; Huiling Sun; Guoqi Song; Shukui Wang
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

View more
  2 in total

1.  The role of FASL, BCL-2 and BAX polymorphisms in brazilian patients with prostate cancer and benign prostatic hyperplasia.

Authors:  Gabriela Kniphoff da Silva Lawisch; Vanderlei Biolchi; Gabriela Kaufmann; Gabriela Nicolai; Eduarda Capitaneo; Thais Regina Rosembach; Janaina Zang; Ilma Simoni Brum; José Artur Bogo Chies
Journal:  Mol Biol Rep       Date:  2022-08-21       Impact factor: 2.742

2.  Serum Levels of Soluble Fas and Fas Ligand in Iranian Women with Pre-eclampsia.

Authors:  Elham Masoumi; Asad Mirzaei; Haniyeh Ghaffari-Nazari; Sahar Tahaghoghi-Hajghorbani; Seyed Amir Jalali; Jalil Tavakkol-Afshari
Journal:  Rep Biochem Mol Biol       Date:  2021-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.